APIS®

by sweetbio®

A Bioengineered Wound Product

Known ingredients, proven independently, powerful together.

Made with an intentional synthesis of trusted materials, APIS® is designed to cover and protect wounds, absorb exudate, and create a moist wound environment.

Backed by evidence

Published in multiple peer-reviewed publications demonstrating 4-8 week wound closure across both chronic and acute wounds. [1-4*]

Engineered for use throughout the wound closure cascade

Supports wound closure across the early stages of bacteria and inflammation to the late stages of proliferation and remodeling.[5-7*]

Next level convenience

Supplied in an all-in-one sheet, APIS® is ready to apply in minutes, can be trimmed or folded, and naturally conforms to the wound bed. APIS® resorbs as the wound progresses - no removal needed.

Reimbursement-ready and operationally simple

APIS® billing pathway is available and ready to bill in this evolving reimbursement landscape. Established HCPCS code, A2010, APIS®



Collagen Derivative +
Mānuka Honey + Hydroxyapatite
Like Never Before

- 4-8 week wound closure [1-3*]
- Lower patient-reported pain in Mohs wounds [4*]

Our MX® Technology Fuels APIS®

Designed to address the demands of the healing process

We meticulously deconstructed natural elements to reimagine and rebuild a new biomaterial. Our core technology, MX™, powers APIS®.

Collagen Derivative [8]

A natural, porcine-derived extracellular matrix protein beneficial for cell migration, adhesion and proliferation

Mānuka Honey [9]

100% UMF-certified New Zealand Mānuka honey known for antibacterial and anti-inflammatory effects

Hydroxyapatite [10]

A naturally occurring mineral known to bind proteins and promote healing via angiogenesis

APIS® in Action: Diabetic Foot Ulcer (Heel)

Diabetic foot ulcer on the heel of the right foot of a 60-year-old male with a history of diabetes mellitus, hypertension, peripheral vascular disease, peripheral neuropathy, and obesity. For 12 months, the wound was treated with various wound care products without resolution of closure.

Near complete closure at week 4 with complete closure at week 5. The patient had 5 visits over 5 weeks with a total of 4 APIS® applications.

WOUND CLOSURE PROGRESSION



DAY 0 | WEEK 1 | WEEK 2 | WEEK 4

"Traditionally, my wounds have taken 14-18 weeks to close. After 5 weeks of APIS®, my wound closed. I can easily take a shower again."

– PATIENT FROM THIS CASE

This testimonial represents the experience of one patient only. Individual patient experiences and outcomes may vary.

FDA 510K CLEARED

Under the supervision of a healthcare professional, APIS® is indicated for use in the management of wounds, including

- Full and partial thickness wounds
- Pressure ulcers (stages I-IV)
- Venous stasis ulcers
- Diabetic ulcers
- Surface wounds
- Traumatic wounds (healing by secondary intention)
- Surgical wounds
- Abrasions
- Donor site wounds

SIZING (HCPCS A2010, APIS)



Size	SKU	Billable Units**
1.6 x 1.6 cm	APIS-16x16-2	3 cm^2
2.5 x 2.5 cm	APIS-25x25-2	6 cm^2
4.0 x 4.0 cm	APIS-40x40-2	16 cm^2
5.0 x 5.0 cm	APIS-50x50-2	25 cm^2
6.0 x 8.0 cm	APIS-60x80-2	48 cm^2

CITATIONS

1. Rodriguez et al. Novel bioengineered collagen + Manuka honey + hydroxyapatite sheet for the treatment of lower extremity chronic wounds in an urban hospital wound care setting. 2023.
2. Rodriguez et al. Preliminary clinical evaluation of a novel bioengineered wound product: A focus on the management of lower extremity ulcers. 2020.
3. McMurray et al. Use of a Novel Biomaterial to Enhance Secondary Intention Healing. 2021.
4. Arnaud et al. Novel Biomaterial Containing Gelatin, Manuka Honey, and Hydroxyapatite Enhanced Secondary Intention Healing Versus Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities-A Randomized Controlled Trial: Pilot Study. 2023.
5. Williams et al. A novel bioengineered wound product with in vitro capabilities to reduce bacteria. 2021.
6. Rodriguez et al. Microenvironment influence of a novel bioengineered wound product APIS®: An in vitro analysis of inflammatory marker and growth factor secretion. 2021.
7. Rodriguez et al. A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet. 2022.
8. Dantas et al. 2011; Li et al. 2014; Pezeshki-Modaress et al. 2014; Pezeshki-Modaress et al. 2015
9. Sell et al. 2012; Afrin et al. 2018; Johnston et al. 2018; Minden-Birkenmaier et al. 2018
10. Okabayashi et al. 2009; Majeed et al. 2012; Kawai et al. 2011; Weilin et al. 2016; Tommila et al.2008; Vilardell et al. 2016; Rodriguez et al. 2013 & 2016

* Based on clinical and *in vitro* data; claims have not been cleared by the FDA. Faster wound closure reported in slower healing and chronic wounds compared to standard of care.

** As of 2026, CMS no longer accepts wastage modifiers and providers are only to bill usage for the exact size of the wound

MKT-032 Rev4 / 0626

APIS® by sweetbio®

recoverwithAPIS.com/clinicians
info@sweetbio.com